311 related articles for article (PubMed ID: 22381590)
1. Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL.
Pirruccello M; De Camilli P
Trends Biochem Sci; 2012 Apr; 37(4):134-43. PubMed ID: 22381590
[TBL] [Abstract][Full Text] [Related]
2. OCRL deficiency impairs endolysosomal function in a humanized mouse model for Lowe syndrome and Dent disease.
Festa BP; Berquez M; Gassama A; Amrein I; Ismail HM; Samardzija M; Staiano L; Luciani A; Grimm C; Nussbaum RL; De Matteis MA; Dorchies OM; Scapozza L; Wolfer DP; Devuyst O
Hum Mol Genet; 2019 Jun; 28(12):1931-1946. PubMed ID: 30590522
[TBL] [Abstract][Full Text] [Related]
3. Suppression of intestinal calcium entry channel TRPV6 by OCRL, a lipid phosphatase associated with Lowe syndrome and Dent disease.
Wu G; Zhang W; Na T; Jing H; Wu H; Peng JB
Am J Physiol Cell Physiol; 2012 May; 302(10):C1479-91. PubMed ID: 22378746
[TBL] [Abstract][Full Text] [Related]
4. OCRL-mutated fibroblasts from patients with Dent-2 disease exhibit INPP5B-independent phenotypic variability relatively to Lowe syndrome cells.
Montjean R; Aoidi R; Desbois P; Rucci J; Trichet M; Salomon R; Rendu J; Fauré J; Lunardi J; Gacon G; Billuart P; Dorseuil O
Hum Mol Genet; 2015 Feb; 24(4):994-1006. PubMed ID: 25305077
[TBL] [Abstract][Full Text] [Related]
5. The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.
De Matteis MA; Staiano L; Emma F; Devuyst O
Nat Rev Nephrol; 2017 Aug; 13(8):455-470. PubMed ID: 28669993
[TBL] [Abstract][Full Text] [Related]
6. The cellular and physiological functions of the Lowe syndrome protein OCRL1.
Mehta ZB; Pietka G; Lowe M
Traffic; 2014 May; 15(5):471-87. PubMed ID: 24499450
[TBL] [Abstract][Full Text] [Related]
7. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.
Ooms LM; Horan KA; Rahman P; Seaton G; Gurung R; Kethesparan DS; Mitchell CA
Biochem J; 2009 Apr; 419(1):29-49. PubMed ID: 19272022
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel OCRL isoforms associated with phenotypic differences between Dent disease-2 and Lowe syndrome.
Sakakibara N; Ijuin T; Horinouchi T; Yamamura T; Nagano C; Okada E; Ishiko S; Aoto Y; Rossanti R; Ninchoji T; Awano H; Nagase H; Minamikawa S; Tanaka R; Matsuyama T; Nagatani K; Kamei K; Jinnouchi K; Ohtsuka Y; Oka M; Araki Y; Tanaka T; Harada MS; Igarashi T; Kitahara H; Morisada N; Nakamura SI; Okada T; Iijima K; Nozu K
Nephrol Dial Transplant; 2022 Jan; 37(2):262-270. PubMed ID: 34586410
[TBL] [Abstract][Full Text] [Related]
9. The inositol polyphosphate 5-phosphatases: traffic controllers, waistline watchers and tumour suppressors?
Astle MV; Horan KA; Ooms LM; Mitchell CA
Biochem Soc Symp; 2007; (74):161-81. PubMed ID: 17233589
[TBL] [Abstract][Full Text] [Related]
10. Functional Characterization and Rescue of a Deep Intronic Mutation in OCRL Gene Responsible for Lowe Syndrome.
Rendu J; Montjean R; Coutton C; Suri M; Chicanne G; Petiot A; Brocard J; Grunwald D; Pietri Rouxel F; Payrastre B; Lunardi J; Dorseuil O; Marty I; Fauré J
Hum Mutat; 2017 Feb; 38(2):152-159. PubMed ID: 27790796
[TBL] [Abstract][Full Text] [Related]
11. Decreased urinary excretion of the ectodomain form of megalin (A-megalin) in children with OCRL gene mutations.
Suruda C; Tsuji S; Yamanouchi S; Kimata T; Huan NT; Kurosawa H; Hirayama Y; Tsukaguchi H; Saito A; Kaneko K
Pediatr Nephrol; 2017 Apr; 32(4):621-625. PubMed ID: 27766457
[TBL] [Abstract][Full Text] [Related]
12. Structure and function of the Lowe syndrome protein OCRL1.
Lowe M
Traffic; 2005 Sep; 6(9):711-9. PubMed ID: 16101675
[TBL] [Abstract][Full Text] [Related]
13. Recognition of the F&H motif by the Lowe syndrome protein OCRL.
Pirruccello M; Swan LE; Folta-Stogniew E; De Camilli P
Nat Struct Mol Biol; 2011 Jun; 18(7):789-95. PubMed ID: 21666675
[TBL] [Abstract][Full Text] [Related]
14. Loss of OCRL increases ciliary PI(4,5)P
Prosseda PP; Luo N; Wang B; Alvarado JA; Hu Y; Sun Y
J Cell Sci; 2017 Oct; 130(20):3447-3454. PubMed ID: 28871046
[TBL] [Abstract][Full Text] [Related]
15. Mouse model for Lowe syndrome/Dent Disease 2 renal tubulopathy.
Bothwell SP; Chan E; Bernardini IM; Kuo YM; Gahl WA; Nussbaum RL
J Am Soc Nephrol; 2011 Mar; 22(3):443-8. PubMed ID: 21183592
[TBL] [Abstract][Full Text] [Related]
16. Kidney Tubular Ablation of
Inoue K; Balkin DM; Liu L; Nandez R; Wu Y; Tian X; Wang T; Nussbaum R; De Camilli P; Ishibe S
J Am Soc Nephrol; 2017 May; 28(5):1399-1407. PubMed ID: 27895154
[TBL] [Abstract][Full Text] [Related]
17. OCRL mutation analysis in Italian patients with Lowe syndrome.
Addis M; Loi M; Lepiani C; Cau M; Melis MA
Hum Mutat; 2004 May; 23(5):524-5. PubMed ID: 15108291
[TBL] [Abstract][Full Text] [Related]
18. OCRL localizes to the primary cilium: a new role for cilia in Lowe syndrome.
Luo N; West CC; Murga-Zamalloa CA; Sun L; Anderson RM; Wells CD; Weinreb RN; Travers JB; Khanna H; Sun Y
Hum Mol Genet; 2012 Aug; 21(15):3333-44. PubMed ID: 22543976
[TBL] [Abstract][Full Text] [Related]
19. Insights into the Effect of Lowe Syndrome-Causing Mutation p.Asn591Lys of OCRL-1 through Protein-Protein Interaction Networks and Molecular Dynamics Simulations.
Acosta-Tapia N; Galindo JF; Baldiris R
J Chem Inf Model; 2020 Feb; 60(2):1019-1027. PubMed ID: 31967472
[TBL] [Abstract][Full Text] [Related]
20. All known patient mutations in the ASH-RhoGAP domains of OCRL affect targeting and APPL1 binding.
McCrea HJ; Paradise S; Tomasini L; Addis M; Melis MA; De Matteis MA; De Camilli P
Biochem Biophys Res Commun; 2008 May; 369(2):493-9. PubMed ID: 18307981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
